Glucagon-like peptide-1 and diabetes

Jan 16, 2016·Prevention Science : the Official Journal of the Society for Prevention Research·Luohua JiangUNKNOWN Special Diabetes Program for Indians Diabetes Prevention Demonstration Project

❮ Previous

Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Glucagon-like peptide-1 and diabetes

Abstract

Citations

Recent advancements in drug treatment of obesity

GLP-1-mediated gene therapy approaches for diabetes treatment

Variations in rodent models of type 1 diabetes: islet morphology

Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes

GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response.

Derivation and Evaluation of a Risk-Scoring Tool to Predict Participant Attrition in a Lifestyle Intervention Project

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Related Papers

Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Assessing the cardiovascular safety of diabetes therapies

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.